Payment overview · 2025
General Payments
$96.67
5 reported records · 4 companies
Healthcare provider profile · identity verified
Kirandeep Kaur, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WHITE PLAINS, MD · NPI 1073742102
Verified facts
What the public records show
CMS Open Payments records show Kirandeep Kaur, MD received $96.67 in general payments during 2025 across 5 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 46.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 484 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $44.90 | 46.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.47 | 20.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.15 | 16.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.15 | 16.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $96.67 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $44.90 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.47 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
484 | 57 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 753 | 112 |
| Eliquis | Apixaban | 484 | 57 |
| Furosemide | Furosemide | 470 | 69 |
| Gabapentin | Gabapentin | 459 | 65 |
| Trazodone Hcl | Trazodone Hcl | 432 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 393 | 61 |
| Mirtazapine | Mirtazapine | 360 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 350 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 323 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 298 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 294 | 44 |
| Divalproex Sodium | Divalproex Sodium | 290 | 44 |
| Potassium Chloride | Potassium Chloride | 266 | 47 |
| Famotidine | Famotidine | 261 | 47 |
| Citalopram Hbr | Citalopram Hydrobromide | 260 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 257 | 25 |
| Levetiracetam | Levetiracetam | 229 | 30 |
| Baclofen | Baclofen | 217 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 199 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 190 | 24 |
| Lisinopril | Lisinopril | 187 | 26 |
| Montelukast Sodium | Montelukast Sodium | 184 | 25 |
| Sertraline Hcl | Sertraline Hcl | 165 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 140 | 26 |
| Metformin Hcl | Metformin Hcl | 130 | 17 |
| Donepezil Hcl | Donepezil Hcl | 126 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 121 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 117 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 116 | 13 |
| Buspirone Hcl | Buspirone Hcl | 115 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 115 | 22 |
| Xarelto | Rivaroxaban | 114 | 14 |
| Tradjenta | Linagliptin | 112 | suppressed |
| Carvedilol | Carvedilol | 108 | 21 |
| Latanoprost | Latanoprost | 99 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 97 | 11 |
| Januvia | Sitagliptin Phosphate | 97 | suppressed |
| Losartan Potassium | Losartan Potassium | 92 | 22 |
| Omeprazole | Omeprazole | 92 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 87 | 26 |
| Finasteride | Finasteride | 75 | 12 |
| Allopurinol | Allopurinol | 73 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 71 | 18 |
| Pregabalin | Pregabalin | 70 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 70 | suppressed |
| Lactulose | Lactulose | 69 | suppressed |
| Acetic Acid | Acetic Acid | 63 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 61 | 35 |
| Ropinirole Hcl | Ropinirole Hcl | 60 | suppressed |
| Primidone | Primidone | 50 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 48 | suppressed |
| Lidocaine | Lidocaine | 48 | 13 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 47 | 45 |
| Midodrine Hcl | Midodrine Hcl | 47 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 46 | suppressed |
| Prednisone | Prednisone | 46 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 29 |
| Digoxin | Digoxin | 45 | suppressed |
| Memantine Hcl | Memantine Hcl | 45 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 45 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 44 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 27 |
| Simvastatin | Simvastatin | 42 | suppressed |
| Bumetanide | Bumetanide | 41 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 40 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 14 |
| Metolazone | Metolazone | 39 | suppressed |
| Novolog Flexpen | Insulin Aspart | 39 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 38 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 38 | 15 |
| Lorazepam | Lorazepam | 38 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 16 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 37 | suppressed |
| Entresto | Sacubitril/Valsartan | 35 | suppressed |
| Methimazole | Methimazole | 35 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 34 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 22 |
| Celecoxib | Celecoxib | 29 | suppressed |
| Ozempic | Semaglutide | 29 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 29 | suppressed |
| Carbamazepine | Carbamazepine | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 26 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Scopolamine | Scopolamine | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Lacosamide | Lacosamide | 24 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 24 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 23 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 20 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 20 | 14 |
| Meropenem | Meropenem | 20 | suppressed |
| Multaq | Dronedarone Hcl | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Nystop | Nystatin | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Timolol Maleate | Timolol Maleate | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Ssd | Silver Sulfadiazine | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 13 |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 16 | 16 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Water | Water For Irrigation,sterile | 14 | suppressed |
| Budesonide Dr | Budesonide | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 12 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Daptomycin | Daptomycin | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Valproic Acid | Valproic Acid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $96.67 · 5 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABRYSVO, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Ozempic, PREVNAR 20, Rybelsus | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error